AAM All Access Podcast - Dan Leonard speaks with Mary Beth Powers, President and CEO of CMMB.

The Generic Drug User Fee Amendments (GDUFA III)

GDUFA aims to put FDA’s generic drug program on a firm financial footing by enabling FDA to assess user fees to fund critical and measurable enhancements to the performance of FDA’s generic drugs program, bringing greater predictability and timeliness to the review of generic drug applications. As a direct outcome, the generic drugs program has increased patient access to safe, high-quality and affordable generic medicines. This document explains the program and how the generics industry works with FDA to improve access.

View Fact Sheet

The GDUFA III Commitment Letter can be found here.

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.